A team of scientists from the Institute of Nano Science & Technology (INST) has developed nanorods from the nonsteroidal anti-inflammatory drug (NSAID) Aspirin, a popular medication used to reduce pain, fever, or inflammation and found it to be an effective non–invasive small molecule-based nanotherapeutics against cataract.
Daily Current Affairs Quiz 2020
Key-Points
Their research published in the Journal of Materials Chemistry B could help prevent cataracts in an economical and less complicated way.
They have used the anti-aggregation ability of self-build aspirin nanorods as an effective non –invasive small molecule-based nanotherapeutics against cataract.
Aspirin nanorods prevent the aggregation of crystallin protein and various peptides derived from its fragmentation, which play a crucial role in cataract formation.
They prevent the protein/peptide aggregation through biomolecular interactions, which convert beta-turn like the structure of the crystallin peptides, responsible for amyloid formation into coils and helices, those fail to aggregate.
As with aging and under various conditions, the lens protein crystallin aggregates to form opaque structures in the eye lens, which impairs vision and cause cataract.
Many natural compounds have already been reported as potential aggregation inhibitors for crystallin aggregation, but the utility of nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin in this direction will open a new paradigm.
In addition, aspirin nanorods due to their nano-size will enhance bioavailability, improve drug loading, lower toxicity, etc.
Hence, the delivery of the aspirin nanorods as eye drops is going to serve as an effective and viable option to treat cataract non-invasively.